サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1554191

劇症型抗リン脂質抗体症候群の市場規模、シェア、動向分析レポート：治療別、最終用途別、地域別、セグメント別予測、2024年～2030年

Catastrophic Antiphospholipid Syndrome Market Size, Share & Trends Analysis Report By Treatment (Anticoagulants, Immunosuppressive Therapy, Plasma Exchange Therapy), By End-use (Hospitals, Clinics), By Region, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 100 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.54円
劇症型抗リン脂質抗体症候群の市場規模、シェア、動向分析レポート：治療別、最終用途別、地域別、セグメント別予測、2024年～2030年
出版日: 2024年08月27日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

劇症型抗リン脂質抗体症候群市場の成長と動向：

Grand View Research社の最新レポートによると、世界の劇症型抗リン脂質抗体症候群の市場規模は2030年までに89億9,000万米ドルに達すると予測され、2024年から2030年までのCAGRは10.7％で成長すると予測されています。

同市場は、この希少で生命を脅かす自己免疫疾患の診断、治療、管理に関連する様々な側面を包含しています。

致命的抗リン脂質症候群（CAPS）市場では、効果的な治療オプションに対する需要の高まりが重要です。患者や医療提供者は、急速な進行や多臓器病変など、CAPSがもたらす特有の課題に対処できる革新的な治療法を積極的に求めています。臨床試験では、本症候群に関連する重篤な血栓性イベントを軽減する標的療法の開発に焦点が当てられています。

自己免疫疾患の有病率の上昇は、市場の成長を促進すると予想されます。自己免疫疾患は、身体が誤って組織を攻撃する異常な免疫反応を伴う。自己免疫疾患の一種であるAPSは、過敏性腸症候群（IBS）などの消化器系の問題を含む合併症を引き起こす可能性があります。クローン病・大腸炎カナダによると、2023年には322,600人以上のカナダ人が炎症性腸疾患（IBD）と共に生活していると推定され、これは全人口の約0.82％に相当します。

劇症型抗リン脂質抗体症候群市場レポート・ハイライト

  • 治療法に基づくと、静脈内免疫グロブリン（IVIG）セグメントが2023年に36.93%の最大売上シェアで市場をリードしました。IVIGの有効性は、難治性CAPS患者が抗凝固療法やコルチコステロイドなどの他の治療と併用してこの治療を受けた後に改善を示したさまざまな臨床例によって裏付けられています。
  • 最終用途別では、病院分野が2023年に62.80%の最大売上シェアで市場を牽引しました。自己免疫疾患の有病率の増加やヘルスケア提供者の間でCAPSに対する認識が高まっていることから、適時介入することで患者の転帰を大幅に改善し、この生命を脅かす疾患に関連する死亡率を低下させることができるため、病院ベースのケアに対する需要が高まっています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 劇症型抗リン脂質抗体症候群市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 劇症型抗リン脂質抗体症候群市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 劇症型抗リン脂質抗体症候群市場：治療別推定・動向分析

  • 世界の劇症型抗リン脂質抗体症候群市場：治療ダッシュボード
  • 世界の劇症型抗リン脂質抗体症候群市場：治療変動分析
  • 世界の劇症型抗リン脂質抗体症候群市場：治療別収益
  • 抗凝固剤
  • 免疫抑制療法
  • 血漿交換療法（血漿交換療法）
  • 静脈内免疫グロブリン（IVIG）
  • その他の治療

第5章 劇症型抗リン脂質抗体症候群市場：最終用途別推定・動向分析

  • 世界の劇症型抗リン脂質抗体症候群市場：最終用途ダッシュボード
  • 世界の劇症型抗リン脂質抗体症候群市場：最終用途変動分析
  • 最終用途別収益
  • 病院
  • クリニック
  • その他

第6章 劇症型抗リン脂質抗体症候群市場：治療および最終用途別の地域別推定・動向分析

  • 地域ダッシュボード
  • 市場規模、予測動向分析、2018年から2030年：
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第7章 競合情勢

  • 企業/競合の分類
  • ベンダー情勢
    • 主要販売代理店およびチャネルパートナーのリスト
    • 主要企業の市場シェア分析、2023年
    • Pfizer
    • Abbott
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Boehringer Ingelheim International GmbH
    • Novartis AG
    • Merck KGaA
    • AbbVie Inc.
    • F. Hoffmann-La Roche
    • Johnson &Johnson Services, Inc.
図表

List of Tables

  • Table 1. List of abbreviation
  • Table 2. North America Catastrophic antiphospholipid syndrome market, by region, 2018 - 2030 (USD Million)
  • Table 3. North America Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 4. North America Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 5. U.S. Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 6. U.S. Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 7. Canada Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 8. Canada Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 9. Mexico Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 10. Mexico Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 11. Europe Catastrophic antiphospholipid syndrome market, by region, 2018 - 2030 (USD Million)
  • Table 12. Europe Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 13. Europe Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 14. Germany Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 15. Germany Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 16. UK Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 17. UK Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 18. France Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 19. France Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 20. Italy Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 21. Italy Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 22. Spain Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 23. Spain Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 24. Denmark Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 25. Denmark Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 26. Sweden Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 27. Sweden Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 28. Norway Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 29. Norway Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 30. Asia Pacific Catastrophic antiphospholipid syndrome market, by region, 2018 - 2030 (USD Million)
  • Table 31. Asia Pacific Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 32. Asia Pacific Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 33. China Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 34. China Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 35. Japan Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 36. Japan Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 37. India Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 38. India Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 39. South Korea Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 40. South Korea Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 41. Australia Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 42. Australia Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 43. Thailand Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 44. Thailand Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 45. Latin America Catastrophic antiphospholipid syndrome market, by region, 2018 - 2030 (USD Million)
  • Table 46. Latin America Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 47. Latin America Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 48. Brazil Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 49. Brazil Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 50. Argentina Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 51. Argentina Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 52. MEA Catastrophic antiphospholipid syndrome market, by region, 2018 - 2030 (USD Million)
  • Table 53. MEA Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 54. MEA Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 55. South Africa Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 56. South Africa Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 57. Saudi Arabia Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 58. Saudi Arabia Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 59. UAE Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 60. UAE Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)
  • Table 61. Kuwait Catastrophic antiphospholipid syndrome market, by treatment, 2018 - 2030 (USD Million)
  • Table 62. Kuwait Catastrophic antiphospholipid syndrome market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modeling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Catastrophic antiphospholipid syndrome market: market outlook
  • Fig. 7 Catastrophic antiphospholipid syndrome competitive insights
  • Fig. 8 Parent market outlook
  • Fig. 9 Related/ancillary market outlook
  • Fig. 10 Catastrophic antiphospholipid syndrome market driver impact
  • Fig. 11 Catastrophic antiphospholipid syndrome market restraint impact
  • Fig. 12 Catastrophic antiphospholipid syndrome market: Treatment movement analysis
  • Fig. 13 Catastrophic antiphospholipid syndrome market: Treatment outlook and key takeaways
  • Fig. 14 Anticoagulants market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Immunosuppressive therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Plasma exchange therapy (plasmapheresis) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Intravenous immunoglobulin (IVIG) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Other treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Catastrophic antiphospholipid syndrome market: End Use movement analysis
  • Fig. 20 Catastrophic antiphospholipid syndrome market: End Use outlook and key takeaways
  • Fig. 21 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Global catastrophic antiphospholipid syndrome market: Regional movement analysis
  • Fig. 25 Global catastrophic antiphospholipid syndrome market: Regional outlook and key takeaways
  • Fig. 26 Global catastrophic antiphospholipid syndrome market share and leading players
  • Fig. 27 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. key country dynamics
  • Fig. 29 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Canada key country dynamics
  • Fig. 31 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico key country dynamics
  • Fig. 33 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 UK key country dynamics
  • Fig. 36 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Germany key country dynamics
  • Fig. 38 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 France key country dynamics
  • Fig. 40 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Italy key country dynamics
  • Fig. 42 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Spain key country dynamics
  • Fig. 44 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark key country dynamics
  • Fig. 46 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Sweden key country dynamics
  • Fig. 48 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Norway key country dynamics
  • Fig. 50 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 China key country dynamics
  • Fig. 53 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Japan key country dynamics
  • Fig. 55 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 India key country dynamics
  • Fig. 57 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Thailand key country dynamics
  • Fig. 59 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 South Korea key country dynamics
  • Fig. 61 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Australia key country dynamics
  • Fig. 63 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Brazil key country dynamics
  • Fig. 66 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Argentina key country dynamics
  • Fig. 68 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 South Africa key country dynamics
  • Fig. 71 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Saudi Arabia key country dynamics
  • Fig. 73 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 UAE key country dynamics
  • Fig. 75 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Kuwait key country dynamics
  • Fig. 77 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Market share of key market players - Catastrophic antiphospholipid syndrome market
目次
Product Code: GVR-4-68040-425-0

Catastrophic Antiphospholipid Syndrome Market Growth & Trends:

The global catastrophic antiphospholipid syndrome market size is anticipated to reach USD 8.99 billion by 2030 and is projected to grow at a CAGR of 10.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market encompasses various aspects related to the diagnosis, treatment, and management of this rare and life-threatening autoimmune disorder.

The rising demand for effective treatment options is critical in the catastrophic antiphospholipid syndrome (CAPS) market. Patients and healthcare providers are actively seeking innovative therapies that can address the unique challenges posed by CAPS, including its rapid progression and multi-organ involvement. The clinical trials are focused on developing targeted therapies that mitigate the severe thrombotic events associated with the syndrome.

The rising prevalence of autoimmune disorders is anticipated to drive the market growth. Autoimmune disorders involve an abnormal immune response where the body mistakenly attacks its tissues. APS, a type of autoimmune disease, can lead to complications, including digestive issues such as irritable bowel syndrome (IBS). According to Crohn's and Colitis Canada, over 322,600 Canadians were estimated to be living with inflammatory bowel disease (IBD) in 2023, which represents about 0.82% of the total population.

Catastrophic Antiphospholipid Syndrome Market Report Highlights:

  • Based on treatment, the intravenous immunoglobulin (IVIG) segment led the market with the largest revenue share of 36.93% in 2023. The efficacy of IVIG is supported by various clinical instances where patients with refractory CAPS showed improvement after receiving this therapy, often in conjunction with other treatments such as anticoagulation and corticosteroids
  • Based on end-use, the hospital segment led the market with the largest revenue share of 62.80% in 2023. The increasing prevalence of autoimmune diseases and the growing awareness of CAPS among healthcare providers fuel the demand for hospital-based care, as timely interventions can significantly improve patient outcomes and reduce mortality rates associated with this life-threatening condition

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment Outlook
    • 2.2.2. End Use Outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Catastrophic Antiphospholipid Syndrome Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. The rising incidence of autoimmune diseases
      • 3.2.1.2. Advancements in diagnostic technologies
      • 3.2.1.3. Increased awareness and education about CAPS
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Limited awareness and understanding of CAPS
      • 3.2.2.2. Challenges in the diagnosis and treatment of CAPS
  • 3.3. Catastrophic Antiphospholipid Syndrome Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Catastrophic Antiphospholipid Syndrome Market: Treatments Estimates & Trend Analysis

  • 4.1. Global Catastrophic Antiphospholipid Syndrome Market: Treatments Dashboard
  • 4.2. Global Catastrophic Antiphospholipid Syndrome Market: Treatments Movement Analysis
  • 4.3. Global Catastrophic Antiphospholipid Syndrome Market by Treatments, Revenue
  • 4.4. Anticoagulants
    • 4.4.1. Anticoagulants market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Immunosuppressive Therapy
    • 4.5.1. Immunosuppressive Therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Plasma Exchange Therapy (Plasmapheresis)
    • 4.6.1. Plasma Exchange Therapy (Plasmapheresis) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Intravenous Immunoglobulin (IVIG)
    • 4.7.1. Intravenous Immunoglobulin (IVIG) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Other Treatment
    • 4.8.1. Other treatment market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Catastrophic Antiphospholipid Syndrome Market: End Use Estimates & Trend Analysis

  • 5.1. Global Catastrophic Antiphospholipid Syndrome Market: End Use Dashboard
  • 5.2. Global Catastrophic Antiphospholipid Syndrome Market: End Use Movement Analysis
  • 5.3. Global Catastrophic Antiphospholipid Syndrome Market Estimates and Forecasts, By End Use, Revenue (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Clinics
    • 5.5.1. Clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Other
    • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Catastrophic Antiphospholipid Syndrome Market: Regional Estimates & Trend Analysis by Treatments, and End Use

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company/Competition Categorization
  • 7.2. Vendor Landscape
    • 7.2.1. List of key distributors and channel partners
    • 7.2.2. Key company market share analysis, 2023
    • 7.2.3. Pfizer
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Abbott
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Bristol-Myers Squibb Company
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Eli Lilly and Company
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Boehringer Ingelheim International GmbH
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Novartis AG
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Merck KGaA
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. AbbVie Inc.
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. F. Hoffmann-La Roche
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives
    • 7.2.12. Johnson & Johnson Services, Inc.
      • 7.2.12.1. Company overview
      • 7.2.12.2. Financial performance
      • 7.2.12.3. Product benchmarking
      • 7.2.12.4. Strategic initiatives